Nebivolol and Endothelial Regulation of Fibrinolysis (NERF)
Overview[ - collapse ][ - ]
Purpose | The investigators hypothesize that nebivolol will improve endothelial t-PA release in adult humans with elevated blood pressure to a greater extent than either metoprolol or placebo. The investigators further hypothesize that the improvement in the capacity of the vascular endothelium to release t-PA with nebivolol is mediated, in part, by the compound's antioxidant properties. |
---|---|
Condition | Prehypertension Hypertension |
Intervention | Drug: Nebivolol Drug: Metoprolol Drug: Placebo |
Phase | Phase 4 |
Sponsor | University of Colorado, Boulder |
Responsible Party | University of Colorado, Boulder |
ClinicalTrials.gov Identifier | NCT01595516 |
First Received | March 5, 2012 |
Last Updated | May 8, 2012 |
Last verified | May 2012 |
Tracking Information[ + expand ][ + ]
First Received Date | March 5, 2012 |
---|---|
Last Updated Date | May 8, 2012 |
Start Date | February 2012 |
Estimated Primary Completion Date | February 2014 |
Current Primary Outcome Measures | Changes from baseline in endothelial t-PA release [Time Frame: t-PA release will be measured at week 3 (before the 12 week drug or placebo intervention) and at week 15 (after the 12 week drug or placebo intervention).] [Designated as safety issue: No]t-PA release is measured in response the bradykinin, sodium nitroprusside, vitamin C and bradykinin+vitamin C |
Current Secondary Outcome Measures | Not Provided |
Descriptive Information[ + expand ][ + ]
Brief Title | Nebivolol and Endothelial Regulation of Fibrinolysis (NERF) |
---|---|
Official Title | Nebivolol and Endothelial Regulation of Fibrinolysis |
Brief Summary | The investigators hypothesize that nebivolol will improve endothelial t-PA release in adult humans with elevated blood pressure to a greater extent than either metoprolol or placebo. The investigators further hypothesize that the improvement in the capacity of the vascular endothelium to release t-PA with nebivolol is mediated, in part, by the compound's antioxidant properties. |
Detailed Description | Not Provided |
Study Type | Interventional |
Study Phase | Phase 4 |
Study Design | Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor) |
Condition |
|
Intervention | Drug: Nebivolol 5 mg tablet to be taken by mouth once per day for 12 weeks Other Names: BystolicDrug: Metoprolol 100 mg tablet to be taken by mouth once per day for 12 weeks Other Names: Toprol-XLDrug: Placebo Gelatin capsule to be taken by mouth once per day for 12 weeks |
Study Arm (s) |
|
Recruitment Information[ + expand ][ + ]
Recruitment Status | Recruiting |
---|---|
Estimated Enrollment | 54 |
Estimated Completion Date | February 2014 |
Estimated Primary Completion Date | February 2014 |
Eligibility Criteria | Inclusion Criteria: - Subjects will be men and women of all races and ethnic backgrounds aged 45-65 years. - Subjects will be prehypertensive/hypertensive defined as resting systolic blood pressure >125 mmHg and <160 mmHg and/or diastolic >80 mmHg and <100 mmHg. - All of the women in the study will be postmenopausal and not receiving hormone replacement therapy (HRT) currently or in the preceding 3-year period. - Candidates will be sedentary as determined from the Stanford Physical Activity Questionnaire (<35 kcal/wk) and will not have engaged in any program of regular physical activity for at least 1 year prior to the study. Exclusion Criteria: - Candidates who smoke (currently or in the past 7 years), report more than low-risk alcohol consumption as defined as no more than 14 standard drinks/wk and no more than 4 standard drinks/day for men and 7 standard drinks/wk and 3 standard drinks/day for women (a standard drink is defined as 12 ounces of beer, 5 ounces of wine, 1½ ounces of 80-proof distilled spirits). - Potential candidates who are taking cardiovascular-acting (i.e. statins, blood pressure medication and aspirin) medications will not be eligible. - Fasting plasma glucose >126 mg/dL. - Potential candidates with a resting heart rate of < 50 beats/minute will be excluded. - Use of hormone replacement therapy. - In hypertensive subjects, a seated systolic blood pressure >160 mmHg or a seated diastolic blood pressure >100 mmHg will be excluded. |
Gender | Both |
Ages | 45 Years |
Accepts Healthy Volunteers | Accepts Healthy Volunteers |
Contacts | Contact: Jared Greiner, M.S. 303-735-4955 jared.greiner@colorado.edu |
Location Countries | United States |
Administrative Information[ + expand ][ + ]
NCT Number | NCT01595516 |
---|---|
Other Study ID Numbers | BYS-MD-72 |
Has Data Monitoring Committee | Yes |
Information Provided By | University of Colorado, Boulder |
Study Sponsor | University of Colorado, Boulder |
Collaborators | Forest Laboratories |
Investigators | Principal Investigator: Christopher DeSouza, Ph.D. University of Colorado at Boulder |
Verification Date | May 2012 |
Locations[ + expand ][ + ]
UC-Boulder Clinical and Translational Research Center | Boulder, Colorado, United States, 80309 | 303-735-3056Principal Investigator: Christopher DeSouza, Ph.D. Recruiting |
---|